While Actinogen’s programs remain at an early stage, the company is a potential takeover target. Last year, Abbvie, Takeda and Eli Lilly all executed pre-clinical Alzheimer’s deals.“Big pharma in the past has said ‘we like what you do, but bring us a signal that your hypothesis has some clinical substance’,” Dr Ketelbey says.Xanahes trial lead investigator, Prof Michael Woodward from Melbourne’s Austin Health, says that given the many past failures in the development of Alzheimer’s drugs, the Xanahes results “renewed hope for a treatment breakthrough for this devastating disease”.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)